Quick search in Citations
This JournalAnywhereCitation
Advanced Search
Research Article
Originally Published 19 March 2018
Free Access

A Screening Approach to Identify Clinically Actionable Variants Causing Congenital Heart Disease in Exome Data

Justin O. Szot, BSc, PhD, Hartmut Cuny, PhD, Gillian M. Blue, PhD, David T. Humphreys, BSc, PhD, Eddie Ip, BSc, Katrina Harrison, BSc, MSc, Gary F. Sholler, MBBS, FRACP, … Show All … , Eleni Giannoulatou, MEng, MPhil, DPhil, Paul Leo, PhD, Emma L. Duncan, MBBS, PhD, Duncan B. Sparrow, BSc, PhD, Joshua W.K. Ho, BSc, PhD, Robert M. Graham, MBBS, MD, Nicholas Pachter, MBChB, MD, Gavin Chapman, BSc, PhD, David S. Winlaw, MBBS, MD, FRACS, and Sally L. Dunwoodie, BSc, PhDAuthor Info & Affiliations
Circulation: Genomic and Precision Medicine
Volume 11, Number 3
https://doi.org/10.1161/CIRCGEN.117.001978
Track CitationsAdd to favorites
PDF/EPUB

Abstract

Background:

Congenital heart disease (CHD)—structural abnormalities of the heart that arise during embryonic development—is the most common inborn malformation, affecting ≤1% of the population. However, currently, only a minority of cases can be explained by genetic abnormalities. The goal of this study was to identify disease-causal genetic variants in 30 families affected by CHD.

Methods:

Whole-exome sequencing was performed with the DNA of multiple family members. We utilized a 2-tiered whole-exome variant screening and interpretation procedure. First, we manually curated a high-confidence list of 90 genes known to cause CHD in humans, identified predicted damaging variants in genes on this list, and rated their pathogenicity using American College of Medical Genetics and Genomics-Association for Molecular Pathology guidelines.

RESULTS:

In 3 families (10%), we found pathogenic variants in known CHD genes TBX5, TFAP2B, and PTPN11, explaining the cardiac lesions. Second, exomes were comprehensively analyzed to identify additional predicted damaging variants that segregate with disease in CHD candidate genes. In 10 additional families (33%), likely disease-causal variants were uncovered in PBX1, CNOT1, ZFP36L2, TEK, USP34, UPF2, KDM5A, KMT2C, TIE1, TEAD2, and FLT4.

Conclusions:

The pathogenesis of CHD could be explained using our high-confidence CHD gene list for variant filtering in a subset of cases. Furthermore, our unbiased screening procedure of family exomes implicates additional genes and variants in the pathogenesis of CHD, which suggest themselves for functional validation. This 2-tiered approach provides a means of (1) identifying clinically actionable variants and (2) identifying additional disease-causal genes, both of which are essential for improving the molecular diagnosis of CHD.

Introduction

See Editorial by Paige et al

Clinical Perspective

Providing a genetic diagnosis helps anticipate patient outcomes and improves clinical care. In the context of congenital heart disease (CHD), the majority of sporadic cases are not offered genetic testing and only limited genetic counseling, partly because of the perception that the yield is low. To address the unmet need for efficient and actionable genetic diagnosis in a clinical setting, we curated a dynamic high-confidence list of genes (hcCHD genes list), which when mutated in humans result in CHD. Applying this list in the context of the standards and guidelines for clinical interpretation of sequence variants as defined by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, our genetic diagnostic approach streamlines clinical interpretation, efficiently identifying clinically actionable causes of disease, which may be directly relayed to families for reproductive planning, disease management, and prognostic purposes. We used this approach on exome data from a cohort of 30 Australian families with sporadic or familial CHD. We identified a causative genetic variant in 3 of 30 cases. To further empower the molecular diagnosis of CHD, we additionally analyzed entire exomes comprehensively within a defined framework. We addressed rarity, predicted-pathogenicity, and segregation with disease, thereby implicating a likely disease-causal variant in an additional 10 of 30 families. These complementary approaches highlight the utility of exome analysis in CHD cases with clinically relevant findings identified in 13 of 30 (43%). This study highlights the utility of exome sequencing in CHD populations who would not be conventional candidates for such investigations.
Congenital heart disease (CHD) is the most common developmental defect in humans and also one of the most severe causes of infant morbidity, affecting ≈8 per 1000 live births or 1.35 million infants each year worldwide.1 Moreover, with advancements in prenatal diagnosis and surgical corrections, the number of newborn deaths has declined, and more children with CHD survive into adulthood, including those with severe abnormalities of the heart. The recurrence risk is 1% to 10%, indicative of a genetic basis of disease, depending on the type of CHD and whether the father or mother has CHD.2 Therefore, it is necessary to reach a genetic diagnosis in affected families.
Generally, the pathogenesis of CHD is still poorly understood, and in only about one third of cases can an inherited or sporadic genetic abnormality be uncovered as the cause of the defect.3,4 Single gene mutations can cause some cases of both syndromic and isolated CHD, but many other cases are believed to be multifactorial, implicating multigenic or environmental factors in disease causation.4,5 Nonsyndromic CHD characterized by Mendelian inheritance is frequently caused by a monogenic mutation, but most nonsyndromic CHD occurs sporadically.3,5
Massively parallel sequencing technology and variant screening have become widely adopted tools for genetic analysis in research and diagnostics, and a growing number of susceptibility genes causing nonsyndromic types of CHD have been identified.4,6 Unlike past genetic analyses that only focused on single gene loci or a panel of candidate genes, whole-exome sequencing (WES) can provide gene variant frequencies in populations, which in turn give important insights about the true effects of variants, and facilitate the clinical diagnosis of sporadic and Mendelian diseases, respectively.7,8 WES offers advantages over whole-genome sequencing in terms of costs and speed, as well as data volume, analysis, and interpretation.7,9,10 WES has identified many human genes that cause CHD when mutated.11,12 Considering that targeted deletion of >500 mouse genes leads to cardiac structural defects (http://www.informatics.jax.org/), it is expected that exome and genome sequencing will implicate many more human genes in CHD in the future.13 The challenge, however, is to recognize disease-causal variants and distinguish them from numerous benign variants present in every genome. Nevertheless, to quickly obtain diagnostic results for patients or families with CHD, focusing on known disease-causal genes has been reported as a useful approach.14,15
In this study, we exome-sequenced a cohort of 30 Australian families with various forms of sporadic or Mendelian CHD. First, we curated a contemporary high-confidence list of genes known to cause human CHD, and we report how many cases can be explained by damaging variants in these genes. We use the updated standards and guidelines for the clinical interpretation of sequence variants with respect to human diseases developed by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) guidelines16 to rate pathogenicity and thus identify clinically actionable findings. Second, we comprehensively analyzed whole exomes within families to identify potential disease-causative variants in genes not currently considered causal of human CHD but plausible based on known gene function and segregation with disease in families. Our study provides an approach that rapidly yields clinically actionable results and also identifies potentially causal variants that require further information for them to be clinically actionable.

Methods

Because this analysis uses patient samples, the data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study Participants

Ethical approval for this study was obtained from the Sydney Children’s Hospital Network Human Research Ethics Committee (approval number HREC/16/SCHN/73). The cohort consisted of 30 unrelated families of which 18 were recruited at Princess Margaret Hospital for Children, Perth, Australia, and 12 were selected from the Kids Heart Research DNA Bank based at Children’s Hospital at Westmead, Sydney, Australia. Families originating from Perth were recruited at presentation to a preadmission clinic before cardiac surgery. They included individuals with family histories of CHD and sporadic cases, whereas only families with >1 affected family member were selected from the Kids Heart Research DNA Bank in Sydney. Heart defects in all affected individuals were confirmed using echocardiography. In all families, at the minimum, a trio (parents and proband) was analyzed. Principal component analysis confirmed the self-declared ethnicities of all individuals in the cohort (Figure I in the Data Supplement).

Sample Preparation and WES Library Construction

Blood samples were processed at the Kids Heart Research DNA Bank, Sydney. Whole blood samples originating in Perth were transported to Sydney on dry ice. Genomic DNA was extracted as described previously.14 Exome libraries were prepared using the Nextera Rapid Capture Exome kit (Illumina, Inc, San Diego, CA) and sequenced on Illumina HiSeq2000 and HiSeq2500. Sequencing coverage analysis was performed using Bedtools (http://bedtools.readthedocs.io/) in conjunction with custom scripts.

Analysis of Sequencing Data

After exome sequencing, DNA sequence reads were aligned to the human reference genome build hg19 using the Burrows-Wheeler Aligner.17 Single Nucleotide Variant calling was performed using Genome Analysis Toolkit software (Broad Institute, Cambridge, MA) following the germline variation best practices and using the option of HaplotypeCaller. The generated variant call format files from multiple samples were then processed together via a joint genotyping call with Genome Analysis Toolkit to produce 1 multisample variant call format file for all DNA variants. Variants were annotated with various metrics using ANNOVAR (http://annovar.openbioinformatics.org/en/latest/). A count for the number of homozygous variants in the Exome Aggregation Consortium (ExAC) database (http://exac.broadinstitute.org/)18 was incorporated with an in-house custom script. The resulting ANNOVAR-annotation file was split into individual families using an in-house custom script.
A control data set of sequenced exomes was used to help exclude artificial sequencing-derived variants in our samples. The control data consisted of Binary Alignment/Map files from 200 reference exome sequences of similar ethnicity, aligned to hg19 using Novoalign (http://www.novocraft.com), generated in a previous project using the same sequencing machinery. Sequence variants were identified, and a variant frequency table was prepared. We referred to this annotation as the control cohort number of alleles.

Filtering, Prioritization, and Validation of Variants

A list of 90 high-confidence CHD genes known to cause human CHD when mutated was curated based on stringent criteria and termed high-confidence CHD gene list (hcCHD list; see Methods in the Data Supplement; Table I in the Data Supplement for details). The VarSifter tool19 was used to filter variants based on genomic location, allele frequency, inheritance pattern, and in silico predicted damaging consequence. In the first analysis approach (hcCHD Gene Screen), exomes of affected probands were screened for rare variants in genes on our manually curated hcCHD list. Variants were defined as rare if the minor allele frequency was <0.01 (<1%) in the ExAC and 1000 Genomes Project databases.20
In the second analysis approach (Comprehensive Screen), inheritance filters were applied to prioritize rare and damaging variants segregating with disease within any gene, and for each family, all possible Mendelian inheritance models were tested. Minor allele frequency thresholds in ExAC and 1000 Genomes were set to <0.001 (<0.1%) for de novo and autosomal dominant inheritance models and to <0.02 (2%) for autosomal recessive and compound heterozygous models. In addition, thresholds for the homozygous variant count in ExAC and heterozygous count in the control cohort, respectively, were set to <1 for de novo and autosomal dominant, <2 (ExAC) and <4 (control cohort) for compound heterozygous, and <3 (ExAC) and <4 (control cohort) for autosomal recessive inheritance models.
Variants passing population frequency thresholds were checked with the Integrative Genomics Viewer21 to confirm the variant call. Variants in highly polymorphic genes, which have notoriously high false-positive variant calls (eg, mucins), were removed irrespective of read quality. Subsequent consideration of protein-damaging variants first removed synonymous calls. Remaining variants were prioritized in VarSifter by their in silico predicted impact on protein function using the Combined Annotation-Dependent Depletion (CADD)22 and PolyPhen-223 tools. Variants predicted as possibly or probably damaging by PolyPhen-2 (HumVar score, ≥0.446) and having a scaled CADD score of >15 were presumed damaging. Variants lacking PolyPhen-2 and CADD annotations, for example, indels, were checked with MutationTaster224 and excluded if the variant call was incorrect. Candidacy of top-scoring variants in the Comprehensive Screen was further interrogated with respect to known gene function, available animal models, published in vitro evidence for similar gene variants causing protein dysfunction, and tentative associations of previous human gene variants with CHD. Finally, potential disease-causal variants were evaluated according to the ACMG-AMP guidelines.

Results

Clinical Characteristics of the Cohort

In total, 120 individuals from 30 families underwent exome sequencing. In 14 families, no history of CHD was reported, in which case the trio, consisting of the unaffected parents and affected proband, was sequenced. For the remaining 16 families with apparent Mendelian CHD, trios plus individuals with available DNA were sequenced. Extracardiac anomalies were found in a subset of patients, but the majority (44 of 57 affected individuals) had isolated CHD (Table 1). Pedigrees and individual clinical findings are provided (Figure II in the Data Supplement). In all cases, the sequencing was of sufficient coverage for analysis (Table II in the Data Supplement).
Table 1. Clinical Characteristics of the Affected Study Participants
CharacteristicsAffected Individuals (n=57)
n%
Sex
 Men2442
 Women3358
Ethnicity*
 European3358
 East Asian24
 South Asian12
 African35
 Other611
 Not recorded1221
Cardiac lesions†
 Septal defect2137
 Septal defect with minor abnormalities1018
 Malformation of the outflow tract712
 AVSD and variants35
 Obstructive lesion47
 Functional single ventricle24
 Other1018
Extracardiac anomalies
 Developmental delay712
 Dysmorphic features59
 Failure to thrive24
 ECG abnormalities24
 Duodenal atresia12
 Congenital hip dysplasia12
 Tracheomalacia, tongue-tie12
 Abdominal situs inversus with right-sided spleen12
 Tracheoesophageal fistula12
 Premature birth12
 None recorded4477
Family history of CHD
 Yes, other family members affected4375
 No, isolated sporadic case1425
AVSD indicates atrioventricular septal defect; and CHD, congenital heart disease.
*
Self-declared ethnicity and based on family history.
†
The primary cardiac lesions are listed. Other includes all CHD subtypes not covered by any of the categories, such as patent ductus arteriosus, patent foramen ovale, right-sided aortic arch, or aberrant subclavian artery.

hcCHD Gene Screen Identified Clinically Actionable Variants and Other Predicted Damaging Variants in Known CHD-Causing Genes

Genetic variants passing the initial automated quality control threshold of the Genome Analysis Toolkit software (≈50 000 variants per individual) were subjected to a series of filtering steps. Filtering for variants in genes implicated in CHD has been applied previously,25,26 but these gene lists tend to be too inclusive and often include genes only linked to CHD by knock-out mouse models. By contrast, we curated a contemporary, high-confidence list of genes known to cause CHD in humans (hcCHD list) by reviewing publicly available CHD gene panels, gene and phenotype databases, and published literature for genes that, when mutated, have been repeatedly reported to cause CHD in humans. Genes were only included in the hcCHD list if variants in the respective gene were reported as the monogenic cause of CHD (isolated or in the context of a syndrome) in ≥3 independent familial or sporadic cases in ≥2 separate publications. In a few cases, single publications reporting multiple individual de novo or autosomal dominant cases with monogenic causative variants were deemed sufficient for inclusion of the respective gene. Importantly, rare predicted damaging variants in genes on the hcCHD list will attract a pathogenic rating by the ACMG-AMP guidelines if the variant segregates with disease. The hcCHD list includes 90 genes that met our stringent criteria defining a hcCHD gene (Table I in the Data Supplement). Curation of the hcCHD list will be ongoing with an up-to-date list accessible online (https://www.victorchang.edu.au/heart-research/embryology), making this list a valuable resource for diagnostic and research use.
Across the 30 families, 99 rare variants were identified in genes on the hcCHD list. Rare variants, predicted to be damaging by CADD,22 PolyPhen-2,23 and MutationTaster2,24 were identified for further scrutiny (Table III in the Data Supplement). Evidence from the literature supported the candidature of 7 variants that segregated with disease in the respective families (Table 2; Figure II in the Data Supplement). Variants in 3 genes (PTPN11, TBX5, and TFAP2B) are rated pathogenic by the ACMG-AMP guidelines and are thus considered clinically actionable. A de novo missense variant in PTPN11 (NM_002834.4:c.184T>G, p.Y62D), identified in the proband of family 13455 with atrial septal defect, patent ductus arteriosus, and pulmonary valve stenosis (Figure II in the Data Supplement), had been previously documented as pathogenic in ClinVar (SCV000057372.3). A dominantly inherited novel TBX5 stopgain variant (NM_000192.3:c.1221C>G, p.Y407*) was identified in family 00860 with atrial and ventricular septal defects. This variant segregates with disease in all 6 affected family members, and a frameshift variant 38 amino acids further C-terminal has been reported to cause Holt-Oram syndrome, including CHD.27 It is possible that subtle upper limb abnormalities, typical for Holt-Oram syndrome, but only identifiable using radiological imaging, were missed during the clinical examination of family 00860 (Figure II in the Data Supplement).
Table 2. Top Variants Identified in the hcCHD Gene Screen
Family IdentifierGeneModel*Genomic Position†cDNA ChangeAmino Acid ChangeExAC MAF‡PP2 HVAR§CADD‖ACMG ClassCHD Phenotype(s)#
13455PTPN11DN12:112888168T>GY62D0PD26.9PASD, PST, PDA
00860TBX5AD12:114793673C>GY407*0NA40PASD, VSD, MV regurgitation, LV hypoplasia
02946TFAP2BAD**6:50805720G>AR285Q0PD35PPDA
01285NOTCH1AD9:139409016A>GN718S0B18.92VUSMV stenosis, VSD
13430ELNAD**7:73469100c.1150+1G>AIntron5E-05NA12.06VUSAVSD, PDA, PFO
13397TBX20AD7:35288426C>GS136S0NANAVUSASD, VSD, PDA
02669GATA4AD**8:11615804G>AT383T5E-05NANAVUSAS, ASD, AVSD, PFO
White: causal variants in hcCHD genes; and grey: variants of uncertain significance. The 4 VUS are highlighted because they might contribute to an oligogenic scenario based on presence in all affected family members and concordance with previously observed phenotypes. ACMG indicates American College of Medical Genetics and Genomics; AD, autosomal dominant; AMP, Association for Molecular Pathology; AS, aortic stenosis; ASD: atrial septal defect; AVSD, atrioventricular septal defect; B, benign; CADD, combined annotation-dependent depletion; CHD, congenital heart disease; DN, de novo; ExAC, Exome Aggregation Consortium; hcCHD, high-confidence congenital heart disease; LV, left ventricle; MAF, minor allele frequency; MV, mitral valve; NA, not applicable; P, pathogenic; PD, probably damaging; PDA, patent ductus arteriosus; PFO, patent foramen ovale; PP2 HVAR, PolyPhen-2 HumVar predictive score; PS, possibly damaging; PST, pulmonary stenosis; VSD, ventricular septal defect; and VUS, variant of uncertain significance.
*
Model: inheritance model.
†
Genomic Position: refers to the human reference genome build hg19.
‡
ExAC MAF: minor allele frequency in the ExAC database.
§
PP2 HVAR: PD score, ≥0.909; PS score, ≥0.447 and <0.909; B score, ≤0.446.
‖
CADD: scaled CADD score.
ACMG Class: interpretive classification according to the updated guidelines by the ACMG-AMP.
#
CHD Phenotype(s): summarized main phenotypes in the family. For detailed phenotype descriptions, see Figure II in the Data Supplement.
**
Variants with presumed incomplete penetrance.
We also identified a previously described pathogenic TFAP2B variant in family 02946 (NM_003221.3:c.854G>A, p.R285Q, ClinVar: SCV000028717.2), reported to have a dominant-negative effect on the DNA-binding capability of TFAP2B. This variant was present in an obligate parental carrier, potentially indicative of incomplete penetrance, commonly observed in inherited CHD.14 Like the previous report, the TFAP2B variant was found in individuals with patent ductus arteriosus and distinctive facial features of Char syndrome (Figure II in the Data Supplement).28
Variants were identified in NOTCH1, TBX20, ELN, and GATA4 that did not pass PolyPhen-2 and CADD thresholds (Table 2) but were present in all respective affected family members and exhibited phenotypic concordance with respect to the literature (Figure II in the Data Supplement). These variants, rated as variants of uncertain significance according to ACMG-AMP guidelines, may contribute to the overall phenotype as part of digenic or oligogenic scenarios. The remainder of the variants are currently rated variants of uncertain significance or benign because they neither segregate with disease nor pass CADD and PolyPhen-2 thresholds (Table III in the Data Supplement).

Comprehensive Screen Identified Clinically Actionable Variants and Other Predicted Damaging Variants in Families With Sporadic CHD

In a second approach (Comprehensive Screen), each family was analyzed for potential disease-causal variants across all genes in an unbiased way. In 14 families with no history of CHD (proband/parent trios), de novo variants are most likely to cause disease; however, for completeness, all inheritance models were applied, identifying additional variants (Table IV in the Data Supplement). We identified 18 rare de novo variants in 14 probands. Of these variants, 11 were predicted to be damaging (Table IV in the Data Supplement), but only 4 had links to heart development (Table 3; Figure II in the Data Supplement).
Table 3. Top Predicted Damaging Variants Identified in the Comprehensive Screen
Family IdentifierGeneModel*Genomic Position†cDNA ChangeAmino Acid ChangeExAC MAF‡PP2 HVAR§CADD‖ACMG ClassCHD Phenotype(s)#
13455PTPN11DN12:112888168T>GY62D0PD26.9PASD, PST, PDA
00860TBX5AD12:114793673C>GY407*0NA40PASD, VSD, MV regurgitation, LV hypoplasia
02946TFAP2BAD**6:50805720G>AR285Q0PD35PPDA
13467PBX1DN1:164768976G>CR184P0PD33PTOF
13478CNOT1DN16:58612645T>GH514Q0PD20.8LPAVSD, DORV, PST
13481ZFP36L2DN2:43452311G>AR211H0PD16.53LPAS
13397TEKAD9:27212762G>AR915H0PD35PASD, VSD, PDA
02944USP34AD2:61607455C>TA288V0PD23.9LPASD, PST
02567UPF2AD10:11997475T>GI869S0PD22.7LPPDA, PFO
01179KDM5AAD12:404795C>TR1467W0PD20.1VUSPFO, TOF, VSD
 KMT2CAD7:151841883A>TQ4753L0PS16.91VUS 
02529TIE1AD**1:43777344delCV448Cfs*90NANALPASD, PAPVC, PLSVC
13430TEAD2AD**19:49845739C>TR399*0NA31LPAVSD, PDA, PFO, VSD
03293††FLT4AD**5:180047670delGGT insTG781Vfs*180NANALPTOF
White: pathogenic variants in hcCHD genes; and grey: likely causal variants in genes with supportive evidence in the literature (Figure II in the Data Supplement). ACMG indicates American College of Medical Genetics and Genomics; AD, autosomal dominant; AMP, Association for Molecular Pathology; AS, aortic stenosis; ASD, atrial septal defect; AVSD, atrioventricular septal defect; B, benign; CADD, combined annotation-dependent depletion; CHD, congenital heart disease; DORV, double outlet right ventricle; DN, de novo; ExAC, Exome Aggregation Consortium; hcCHD, high-confidence congenital heart disease; LP, likely pathogenic; LV, left ventricle; MAF, minor allele frequency; MV, mitral valve; NA, not applicable; P, pathogenic; PAPVC, partial anomalous pulmonary venous connection; PD, probably damaging; PDA, patent ductus arteriosus; PFO, patent foramen ovale; PLSVC, persistent left superior vena cava; PP2 HVAR, PolyPhen-2 HumVar predictive score; PS, possibly damaging; PST, pulmonary stenosis; TOF, Tetralogy of Fallot; VSD, ventricular septal defect; and VUS, variant of uncertain significance.
*
Model: inheritance model.
†
Genomic Position: refers to the human reference genome build hg19.
‡
ExAC MAF: Minor allele frequency in the ExAC database.
§
PP2 HVAR: PolyPhen-2 HumVar predictive score. PD score, ≥0.909; PS score, ≥0.447 and <0.909; B score, ≤0.446.
‖
CADD: scaled CADD score.
ACMG Class: interpretive classification according to the updated guidelines by the ACMG-AMP.
#
CHD Phenotype(s), summarized main phenotypes of the family. For detailed phenotype descriptions, see Figure II in the Data Supplement.
**
Variants with presumed incomplete penetrance.
††
Further details about family 03293 will be submitted for publication elsewhere.
Among them is the de novo variant in PTPN11 also identified in the hcCHD Gene Screen. A missense variant in PBX1 convincingly explains the cardiac defect, Tetralogy of Fallot with absent pulmonary valve, in proband 13467. PBX1 (Pre-B-cell leukemia transcription factor 1) is an evolutionarily highly conserved homeodomain-containing transcription factor, which when deleted in mouse, results in similar cardiac phenotypes (Figure II in the Data Supplement).29–31 In 4 other families, we identified predicted damaging de novo variants in genes that have not yet been linked to human CHD (Table IV in the Data Supplement). Of these, 2 missense variants in CNOT1 and ZFP36L2 have supportive evidence in the literature (Figure II in the Data Supplement, families 13478 and 13481). Accordingly, variants in PTPN11 and PBX1 were rated pathogenic, according to ACMG-AMP guidelines, and are thus clinically actionable, whereas CNOT1 and ZFP36L2 were rated likely pathogenic (Table 3).
We also applied a filter for recessive inheritance and identified 4 homozygous variants predicted to be damaging. None of the affected genes have a known link to CHD. For a compound heterozygous inheritance model, we identified predicted damaging candidate variants in 7 genes (Table IV in the Data Supplement), also none of which have a known link to CHD. Filtering variants for an autosomal dominant inheritance model that assumes incomplete penetrance in the parental generation returned large variant numbers. In these cases, variants in the hcCHD genes were given priority, but none were compelling candidates (Table IV in the Data Supplement).

Comprehensive Screen Identified Clinically Actionable Variants and Other Predicted Damaging Variants in Families With a History of CHD

The Comprehensive Screen was also applied to 16 families with a history of structural heart defects. As above, for completeness, all inheritance models were applied, identifying additional variants (Table V in the Data Supplement). We identified 1545 rare autosomal dominant variants in 16 probands. Of these, 428 variants were predicted to be damaging, and top candidates present in all affected family members, with supportive evidence in the literature, are highlighted in Table 3.
In 5 families, we identified predicted damaging variants that segregate with disease. In 2 families, variants explain the cardiac lesions: the stopgain in TBX5 as identified with the hcCHD Gene Screen and a known pathogenic missense variant in TEK.
TEK (NM_000459.4:c.2744G>A, p.R915H; SCV000044247.1; Table 3), previously described to cause ventricular septal defects and cutaneomucosal venous malformations,32 was identified in a trio within which the mother and proband had ventricular septal defects. This and the cardiovascular phenotype of Tek-null mice33 are strong evidence that the TEK variant is disease-causal in this trio.
We found compelling candidates that segregate with disease in 3 families: a missense variant in USP34, UPF2, and a digenic combination of 2 missense variants in KDM5A and KMT2C (Table 3). The novel USP34 variant (NM_014709.3:c.863C>T, p.A288V) segregates with disease, and a similar missense variant in this gene was previously reported in a patient with diverse CHDs.12 Cardiac-specific silencing of this gene in Drosophila resulted in significant embryonic lethality, highlighting a possible role of this gene in human heart development.34
The novel UPF2 variant (NM_080599.2:c.2606T>G, p.I869S) is nearby a previously identified variant E858R that perturbs the UPF2 (Regulator of nonsense transcripts 2)-UPF3b interaction, necessary for nonsense-mediated decay (Figure II in the Data Supplement).35 UPF2 functions as part of the nonsense-mediated mRNA decay surveillance machinery, and, although the function of UPF2 has not yet been assessed in the heart, loss of this gene in mice results in embryonic lethality by midgestation,36 making this variant a compelling candidate.
KDM5A and KMT2C, and their respective variants (NM_001042603.2:c.4399C>T, p.R1467W and NM_170606.2:c.14258A>T, p.Q4753L), may perturb heart development through altered histone methylation (Figure II in the Data Supplement, family 01179).
Accordingly, variants in TBX5 and TEK were rated pathogenic according to ACMG-AMP guidelines and are thus clinically actionable, whereas USP34 and UPF2 were rated likely pathogenic.
The Comprehensive Screen revealed 4 additional likely disease-causal variants in the remaining families with apparent incomplete penetrance of CHD: the TFAP2B missense variant identified with the hcCHD Gene Screen, a single-base deletion in TIE1 leading to a frameshift and truncated protein, a stopgain variant in TEAD2, and an indel in FLT4 (Table 3).
TIE1 (Tyrosine-protein kinase receptor Tie-1) functionally dimerizes with TEK (Angiopoietin-1 receptor) to mediate development and maintenance of the vascular system. Loss of TIE1 in mice results in abnormal heart morphologies, including a thinning of the atrial wall.37,38 In this light, the TIE1 variant (NM_005424.4:c.1341del p.V448Cfs*9) is a likely cause of the septal defects seen in family 02529 (Figure II in the Data Supplement). TEAD2 (Transcriptional enhancer factor TEF-4) regulates cardiomyocyte proliferation and survival during development through the Hippo signaling pathway and regulation of Pax3 and Foxa2 transcription factors.39,40 The novel TEAD2 stopgain (NM_001256659.1:c.1195C>T, p.R399*) is, therefore, a plausible explanation for the CHDs seen in family 13430 (Figure II in the Data Supplement).
Accordingly, the variant in TFAP2B was rated pathogenic according to ACMG-AMP guidelines, and is thus clinically actionable, whereas variants in TIE1, FLT4, and TEAD2 were rated likely pathogenic.
In summary, the hcCHD Gene Screen identified disease-causal variants in 3 cases (1 sporadic and 2 familial), defined as pathogenic by ACMG-AMP guidelines. The Comprehensive Screen also identified these 3 variants and rated them as top candidates in the respective families. Unsurprisingly, the Comprehensive Screen did not identify additional disease-causal variants in hcCHD genes but revealed candidate variants in other genes in a further 10 cases (3 sporadic and 7 familial). In total, we were able to uncover credible disease-causal variants in 3 families with variants in the hcCHD gene list (3 of 30; 10%) and in 10 families with variants in genes not yet considered causal of CHD (10 of 30; 33%; Tables 2 and 3; Figure). Furthermore, the unbiased Comprehensive Screen identified numerous additional rare and predicted damaging variants with no previous association to CHD (Tables IV and V in the Data Supplement).
Figure. Comprehensive 2-tiered whole-exome sequencing analysis to identify disease-causal genetic factors in 30 families with sporadic and familial congenital heart disease (CHD), respectively. Variant filtration utilizing a list of 90 genes known to cause CHD identified 3 disease-causal variants in 3 families (1 sporadic and 2 familial cases). With a comprehensive family-based variant screening procedure, 10 additional potentially causal variant candidates in genes not yet linked to CHD in humans could be identified (3 sporadic and 7 familial cases). hcCHD indicates high-confidence congenital heart disease.

Discussion

Here, we applied 2 approaches to identify disease-causal genetic mutations in 30 Australian families affected with CHD using exome sequencing. The hcCHD Gene Screen focusing on genes known to cause CHD in humans efficiently explained the disease pathogenesis in 10% of cases, and the Comprehensive Screen identifying predicted damaging variants in the whole coding region of the genome detected credible gene candidates potentially causing CHD in an additional 33% of cases.
Currently, clinical genetic testing in this field is restricted to cytogenetic screening of patients with multiple congenital abnormalities, copy number variant (CNV) analysis for severe CHDs associated with known syndromes, and single gene testing in a subset of genes with monogenic syndromic association.41 However, given the complex pathogenesis of CHD, it can be assumed that more genes are involved in heart development and CHD than those currently listed in diagnostic gene panels. To address this unmet need for an up-to-date list defining human CHD genes, we curated the hcCHD list of genes, variants in which will be classified as pathogenic according to ACMG-AMP guidelines if the variant is rare, predicted damaging, and segregates with disease (Table 2).

Performance of Family-Based WES Analysis

The hcCHD Gene Screen identified a gene variant as the definitive cause of CHD in 3 of 30 families (Figure, left). Through subsequent application of the Comprehensive Screen, we identified likely causative variants in 10 additional families (Figure, middle). Although the latter 10 candidate genes have not yet been unequivocally linked to CHD, there is substantial protein function or animal model evidence to indicate a role in human CHD.
Moreover, the Comprehensive Screen returned several additional predicted damaging variants, which we do not currently consider disease-causal because of a lack of data relating them to heart development or the general lack of knowledge about their function (Tables IV and V in the Data Supplement; Figure II in the Data Supplement). Future functional studies, such as analysis of animal models, or assessment of protein function in vitro (Figure), is warranted to determine the actual consequence of these predicted damaging variants.
To accurately evaluate our yield in comparison with previous reports, it is necessary to consider sporadic and familial cases in our cohort separately. Among the 14 families with sporadic CHD, we identified one disease-causal variant within a known CHD gene (PTPN11). With the Comprehensive Screen, we could identify a plausible variant in 3 additional families, yielding an overall diagnosis rate of 29% (4 of 14). This diagnosis rate for sporadic cases exceeds the maximum expected ≈10% contribution by de novo variants, as suggested by recent large-scale studies of sporadic CHD.12,25
Our diagnosis rate was higher for the 16 families with a history of CHD. The hcCHD Gene Screen identified disease-causal variants in 2 known CHD genes (TBX5 and TFAP2B), and the Comprehensive Screen uncovered candidate variants in 7 additional families, yielding an overall diagnosis rate of 56% (9 of 16).
Comparable analyses of familial CHD have achieved successes between 33% and 46%. Because these studies, however, only interrogated variants in known CHD genes (57–69 genes),14,15,42 this statistic is appropriately below that of our unbiased Comprehensive Screen. The apparent outperformance of these studies compared with our hcCHD yield can be somewhat accounted for, similar to our de novo yield, by relative differences in sample sizes, variant filtering, and interpretation, between studies.
In familial cases, monogenic mutations are more likely to be the cause of CHD, especially if the disease occurs across ≥2 generations in a Mendelian pattern. By contrast, sporadic cases are more likely to be multifactorial, involving multiple genetic and nongenetic factors.4,5 Indeed, cumulative data from published reports show that more cases of sporadic CHD remain unresolved by genetic screening than cases of familial CHD.4 The absence of convincing damaging recessive or compound heterozygous genotypes in our study is in line with ≈1% incidence previously reported for nonsyndromic CHD cases with no parental consanguinity.25,26
In contrast to other cohort-based CHD studies, we reported variant pathogenicity in the context of ACMG-AMP standards. We have shown that predicted damaging variants identified in genes on the hcCHD list receive a pathogenic classification and, therefore, are considered causative for diagnostic purposes. As the hcCHD list inevitably grows because of efforts such as our Comprehensive Screen, an increasing number of pathogenic disease-causal variants will be identified. Periodic reinterpretation of clinical exomes in light of new supportive evidence will significantly improve diagnostic success.43 Unlike target panel sequencing, WES data can be reanalyzed when warranted using up-to-date lists, such as the hcCHD list, to achieve higher diagnostic rates.

Limitations

A general limitation of family-based WES variant filtering and analysis is that it assumes a monogenic cause of disease. In cases where no plausible gene variant can be found, it is possible that the disease is caused by ≥2 mutations, which individually need not be particularly rare nor damaging. This has been highlighted in recent studies, utilizing unbiased statistical comparisons from large-scale CHD cohorts,25,26 showing that patients with nonsyndromic CHD carry an exome-wide burden of rare inherited protein-truncating variants. These findings recognize a potential oligogenic contribution to nonsyndromic CHD and may partially account for observed incomplete penetrance. Another limitation of using WES data concerns cases in which CNVs are the underlying genetic factor. CNVs are estimated to explain ≤10% of sporadic CHD, and even ≤25% of syndromic CHD, but their identification requires high-quality whole-genome sequence data or other specific assays.4,6 CNV analysis was attempted from whole-exome sequence data of this cohort, but variant calls were of insufficient quality to be practically interpretable, as is generally known for exome data.44 Finally, pathogenic mutations in noncoding genome regions will not be identified with WES. However, the functional relevance of noncoding variants is largely unknown, and because they are difficult to test, it is likely that the identified causes of CHD will be largely limited to the exome for some time.9 A future approach to overcome these limitations is to sequence the genome, limit initial analysis to the exome, integrate CNV analysis, and analyze noncoding regions when in silico tools to interpret these regions become available.

Conclusions

Filtering WES data using the hcCHD list of genes known to cause CHD quickly identifies variants that are pathogenic according to the ACMG-AMP guidelines and thus are clinically actionable. The hcCHD list, as it is up-to-date, will be invaluable in a diagnostic setting. Therefore, in probands with CHD requiring surgery, with no identified pathogenic CNVs, and their parents, we propose exome sequence analysis of variants in hcCHD genes as a first-line diagnostic approach. The Comprehensive Screen, however, significantly increases the rate of identifying CHD-causing variants, and also implicates additional candidate genes that are likely to be included in the hcCHD list in the future, ultimately improving the rate of patient diagnosis.

Acknowledgments

We are grateful to the families who participated in this research, to Dr David Andrews (Princess Margaret Hospital, Perth), and the individuals and agencies that supported this research.

Supplemental Material

File (circ_gen_11-e001978-small.mp4)
File (circgenetics_circcvg-2017-001978_supp1.pdf)
File (script_for_circ_gen_11-e001978.docx)

References

1.
van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:2241–2247. doi: 10.1016/j.jacc.2011.08.025.
Crossref
PubMed
Google Scholar
2.
Blue GM, Kirk EP, Sholler GF, Harvey RP, Winlaw DS. Congenital heart disease: current knowledge about causes and inheritance. Med J Aust. 2012;197:155–159.
Crossref
PubMed
Google Scholar
3.
Akhirome E, Walton NA, Nogee JM, Jay PY. The complex genetic basis of congenital heart defects. Circ J. 2017;81:629–634. doi: 10.1253/circj.CJ-16-1343.
Crossref
PubMed
Google Scholar
4.
Blue GM, Kirk EP, Giannoulatou E, Sholler GF, Dunwoodie SL, Harvey RP, et al. Advances in the genetics of congenital heart disease: a clinician’s guide. J Am Coll Cardiol. 2017;69:859–870. doi: 10.1016/j.jacc.2016.11.060.
Crossref
PubMed
Google Scholar
5.
Gelb BD, Chung WK. Complex genetics and the etiology of human congenital heart disease. Cold Spring Harb Perspect Med. 2014;4:a013953. doi: 10.1101/cshperspect.a013953.
Crossref
PubMed
Google Scholar
6.
Muntean I, Togănel R, Benedek T. Genetics of congenital heart disease: past and present. Biochem Genet. 2017;55:105–123. doi: 10.1007/s10528-016-9780-7.
Crossref
PubMed
Google Scholar
7.
Petersen BS, Fredrich B, Hoeppner MP, Ellinghaus D, Franke A. Opportunities and challenges of whole-genome and -exome sequencing. BMC Genet. 2017;18:14. doi: 10.1186/s12863-017-0479-5.
Crossref
PubMed
Google Scholar
8.
Trujillano D, Bertoli-Avella AM, Kumar Kandaswamy K, Weiss ME, Köster J, Marais A, et al. Clinical exome sequencing: results from 2819 samples reflecting 1000 families. Eur J Hum Genet. 2017;25:176–182. doi: 10.1038/ejhg.2016.146.
Crossref
PubMed
Google Scholar
9.
Lelieveld SH, Veltman JA, Gilissen C. Novel bioinformatic developments for exome sequencing. Hum Genet. 2016;135:603–614. doi: 10.1007/s00439-016-1658-6.
Crossref
PubMed
Google Scholar
10.
Sun Y, Ruivenkamp CA, Hoffer MJ, Vrijenhoek T, Kriek M, van Asperen CJ, et al. Next-generation diagnostics: gene panel, exome, or whole genome? Hum Mutat. 2015;36:648–655. doi: 10.1002/humu.22783.
Crossref
PubMed
Google Scholar
11.
Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science. 2015;350:1262–1266. doi: 10.1126/science.aac9396.
Crossref
PubMed
Google Scholar
12.
Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, et al. De novo mutations in histone-modifying genes in congenital heart disease. Nature. 2013;498:220–223. doi: 10.1038/nature12141.
Crossref
PubMed
Google Scholar
13.
Andersen TA, Troelsen Kde L, Larsen LA. Of mice and men: molecular genetics of congenital heart disease. Cell Mol Life Sci. 2014;71:1327–1352. doi: 10.1007/s00018-013-1430-1.
Crossref
PubMed
Google Scholar
14.
Blue GM, Kirk EP, Giannoulatou E, Dunwoodie SL, Ho JW, Hilton DC, et al. Targeted next-generation sequencing identifies pathogenic variants in familial congenital heart disease. J Am Coll Cardiol. 2014;64:2498–2506. doi: 10.1016/j.jacc.2014.09.048.
Crossref
PubMed
Google Scholar
15.
LaHaye S, Corsmeier D, Basu M, Bowman JL, Fitzgerald-Butt S, Zender G, et al. Utilization of whole exome sequencing to identify causative mutations in familial congenital heart disease. Circ Cardiovasc Genet. 2016;9:320–329. doi: 10.1161/CIRCGENETICS.115.001324.
Crossref
PubMed
Google Scholar
16.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424. doi: 10.1038/gim.2015.30.
Crossref
PubMed
Google Scholar
17.
Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–1760. doi: 10.1093/bioinformatics/btp324.
Crossref
PubMed
Google Scholar
18.
Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al.; Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291. doi: 10.1038/nature19057.
Crossref
PubMed
Google Scholar
19.
Teer JK, Green ED, Mullikin JC, Biesecker LG. VarSifter: visualizing and analyzing exome-scale sequence variation data on a desktop computer. Bioinformatics. 2012;28:599–600.
Crossref
PubMed
Google Scholar
20.
The Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526:68–74.
Crossref
PubMed
Google Scholar
21.
Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24–26. doi: 10.1038/nbt.1754.
Crossref
PubMed
Google Scholar
22.
Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–315. doi: 10.1038/ng.2892.
Crossref
PubMed
Google Scholar
23.
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–249. doi: 10.1038/nmeth0410-248.
Crossref
PubMed
Google Scholar
24.
Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11:361–362. doi: 10.1038/nmeth.2890.
Crossref
PubMed
Google Scholar
25.
Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet. 2017;49:1593–1601. doi: 10.1038/ng.3970.
Crossref
PubMed
Google Scholar
26.
Sifrim A, Hitz MP, Wilsdon A, Breckpot J, Turki SH, Thienpont B, et al.; INTERVAL Study; UK10K Consortium; Deciphering Developmental Disorders Study. Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing. Nat Genet. 2016;48:1060–1065. doi: 10.1038/ng.3627.
Crossref
PubMed
Google Scholar
27.
Posch MG, Perrot A, Berger F, Ozcelik C. Molecular genetics of congenital atrial septal defects. Clin Res Cardiol. 2010;99:137–147. doi: 10.1007/s00392-009-0095-0.
Crossref
PubMed
Google Scholar
28.
Zhao F, Weismann CG, Satoda M, Pierpont ME, Sweeney E, Thompson EM, et al. Novel TFAP2B mutations that cause Char syndrome provide a genotype-phenotype correlation. Am J Hum Genet. 2001;69:695–703. doi: 10.1086/323410.
Crossref
PubMed
Google Scholar
29.
Slavotinek A, Risolino M, Losa M, Cho MT, Monaghan KG, Schneidman-Duhovny D, et al. De novo, deleterious sequence variants that alter the transcriptional activity of the homeoprotein PBX1 are associated with intellectual disability and pleiotropic developmental defects. Hum Mol Genet. 2017;26:4849–4860. doi: 10.1093/hmg/ddx363.
Crossref
PubMed
Google Scholar
30.
Chang CP, Stankunas K, Shang C, Kao SC, Twu KY, Cleary ML. Pbx1 functions in distinct regulatory networks to pattern the great arteries and cardiac outflow tract. Development. 2008;135:3577–3586. doi: 10.1242/dev.022350.
Crossref
PubMed
Google Scholar
31.
Stankunas K, Shang C, Twu KY, Kao SC, Jenkins NA, Copeland NG, et al. Pbx/Meis deficiencies demonstrate multigenetic origins of congenital heart disease. Circ Res. 2008;103:702–709. doi: 10.1161/CIRCRESAHA.108.175489.
Crossref
PubMed
Google Scholar
32.
Wouters V, Limaye N, Uebelhoer M, Irrthum A, Boon LM, Mulliken JB, et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet. 2010;18:414–420. doi: 10.1038/ejhg.2009.193.
Crossref
PubMed
Google Scholar
33.
Puri MC, Partanen J, Rossant J, Bernstein A. Interaction of the TEK and TIE receptor tyrosine kinases during cardiovascular development. Development. 1999;126:4569–4580.
Crossref
PubMed
Google Scholar
34.
Zhu JY, Fu Y, Nettleton M, Richman A, Han Z. High throughput in vivo functional validation of candidate congenital heart disease genes in Drosophila. Elife. 2017;6:e22617.
Crossref
PubMed
Google Scholar
35.
Boehm V, Haberman N, Ottens F, Ule J, Gehring NH. 3’ UTR length and messenger ribonucleoprotein composition determine endocleavage efficiencies at termination codons. Cell Rep. 2014;9:555–568. doi: 10.1016/j.celrep.2014.09.012.
Crossref
PubMed
Google Scholar
36.
Weischenfeldt J, Damgaard I, Bryder D, Theilgaard-Mönch K, Thoren LA, Nielsen FC, et al. NMD is essential for hematopoietic stem and progenitor cells and for eliminating by-products of programmed DNA rearrangements. Genes Dev. 2008;22:1381–1396. doi: 10.1101/gad.468808.
Crossref
PubMed
Google Scholar
37.
Patan S. TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. Microvasc Res. 1998;56:1–21. doi: 10.1006/mvre.1998.2081.
Crossref
PubMed
Google Scholar
38.
Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376:70–74. doi: 10.1038/376070a0.
Crossref
PubMed
Google Scholar
39.
Landin-Malt A, Benhaddou A, Zider A, Flagiello D. An evolutionary, structural and functional overview of the mammalian TEAD1 and TEAD2 transcription factors. Gene. 2016;591:292–303. doi: 10.1016/j.gene.2016.07.028.
Crossref
PubMed
Google Scholar
40.
Zhang Y, Del Re DP. A growing role for the Hippo signaling pathway in the heart. J Mol Med (Berl). 2017;95:465–472. doi: 10.1007/s00109-017-1525-5.
Crossref
PubMed
Google Scholar
41.
Ito S, Chapman KA, Kisling M, John AS. Appropriate use of genetic testing in congenital heart disease patients. Curr Cardiol Rep. 2017;19:24. doi: 10.1007/s11886-017-0834-1.
Crossref
PubMed
Google Scholar
42.
Jia Y, Louw JJ, Breckpot J, Callewaert B, Barrea C, Sznajer Y, et al. The diagnostic value of next generation sequencing in familial nonsyndromic congenital heart defects. Am J Med Genet A. 2015;167A:1822–1829. doi: 10.1002/ajmg.a.37108.
Crossref
PubMed
Google Scholar
43.
Nambot S, Thevenon J, Kuentz P, Duffourd Y, Tisserant E, Bruel AL, et al. Clinical whole-exome sequencing for the diagnosis of rare disorders with congenital anomalies and/or intellectual disability: substantial interest of prospective annual reanalysis [published online ahead of print November 2, 2017]. Genet Med. doi: 10.1038/gim.2017.162. Available at http://www.ncbi.nlm.nih.gov/pubmed/29095811.
Crossref
Google Scholar
44.
Hong CS, Singh LN, Mullikin JC, Biesecker LG. Assessing the reproducibility of exome copy number variations predictions. Genome Med. 2016;8:82. doi: 10.1186/s13073-016-0336-6.
Crossref
PubMed
Google Scholar

eLetters(0)

eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.

Sign In to Submit a Response to This Article

Information & Authors

Information

Published In

Go to Circulation: Genomic and Precision Medicine
Go to Circulation: Genomic and Precision Medicine
Circulation: Genomic and Precision Medicine
Volume 11 • Number 3 • March 2018
PubMed: 29555671

Copyright

© 2018 American Heart Association, Inc.

History

Received: 5 October 2017
Accepted: 18 January 2018
Published in print: March 2018
Published online: 19 March 2018

Permissions

Request permissions for this article.

Keywords

  1. exome
  2. genetic testing
  3. genetic variation
  4. heart diseases
  5. humans

Subjects

  1. Congenital Heart Disease
  2. Developmental Biology
  3. Genetics
  4. Precision Medicine

Authors

Affiliations

Justin O. Szot, BSc, PhD*
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Hartmut Cuny, PhD*
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Gillian M. Blue, PhD
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
David T. Humphreys, BSc, PhD
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Eddie Ip, BSc
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Katrina Harrison, BSc, MSc
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Gary F. Sholler, MBBS, FRACP
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Eleni Giannoulatou, MEng, MPhil, DPhil
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Paul Leo, PhD
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Emma L. Duncan, MBBS, PhD
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Duncan B. Sparrow, BSc, PhD
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Joshua W.K. Ho, BSc, PhD
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Robert M. Graham, MBBS, MD
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Nicholas Pachter, MBChB, MD
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Gavin Chapman, BSc, PhD†
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
David S. Winlaw, MBBS, MD, FRACS†
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author
Sally L. Dunwoodie, BSc, PhD†
From the Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia (J.O.S., H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.); Faculty of Science (J.O.S., S.L.D.) and Faculty of Medicine (H.C., D.T.H., E.I., E.G., D.B.S., J.W.K.H., R.M.G., G.C., S.L.D.), University of New South Wales, Sydney, New South Wales, Australia, Sydney, New South Wales, Australia; Children’s Hospital at Westmead, Heart Centre for Children (G.M.B., G.F.S., D.S.W.), Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia (G.M.B., G.F.S., D.S.W.); Genetic Services of Western Australia, Perth (K.H., N.P.); Sydney Children’s Hospitals Network, New South Wales, Australia (G.F.S.); Institute of Health and Biomedical Innovation, Queensland University of Technology (P.L., E.L.D.); Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia (E.L.D.); University of Queensland, Brisbane (E.L.D.); and School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia (N.P.).
View all articles by this author

Notes

*
Drs Szot and Cuny contributed equally to this work.
†
Drs Dunwoodie, Chapman, and Winlaw contributed equally to this work.
Circ Genom Precis Med is available at http://circgenetics.ahajournals.org.
Correspondence to: Sally L. Dunwoodie, BSc, PhD, Victor Chang Cardiac Research Institute, Lowy Packer Bldg, 405 Liverpool St, Darlinghurst, Sydney, New South Wales 2010, Australia. E-mail [email protected]

Disclosures

None.

Sources of Funding

This work was supported by the National Health and Medical Research Council; fellowships ID514900 and ID1042002 to Dr Dunwoodie and ID1105271 to Dr Ho, and Program grant ID1074386 to Drs Dunwoodie and Graham); Australian National Heart Foundation (fellowship ID100848 to Dr Ho and ID101204 to Dr Giannoulatou); the Kirby Foundation to Dr Ho; Office of Health and Medical Research New South Wales Government to Dr Dunwoodie; Chain Reaction (the Ultimate Corporate Bike Challenge) to Drs Dunwoodie and Winlaw; Channel 7 Telethon to Drs Dunwoodie and Graham; and the Key Foundation to Dr Dunwoodie.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

    • Seth S. Martin,
    • Aaron W. Aday,
    • Norrina B. Allen,
    • Zaid I. Almarzooq,
    • Cheryl A.M. Anderson,
    • Pankaj Arora,
    • Christy L. Avery,
    • Carissa M. Baker-Smith,
    • Nisha Bansal,
    • Andrea Z. Beaton,
    • Yvonne Commodore-Mensah,
    • Maria E. Currie,
    • Mitchell S.V. Elkind,
    • Wenjun Fan,
    • Giuliano Generoso,
    • Bethany Barone Gibbs,
    • Debra G. Heard,
    • Swapnil Hiremath,
    • Michelle C. Johansen,
    • Dhruv S. Kazi,
    • Darae Ko,
    • Michelle H. Leppert,
    • Jared W. Magnani,
    • Erin D. Michos,
    • Michael E. Mussolino,
    • Nisha I. Parikh,
    • Sarah M. Perman,
    • Mary Rezk-Hanna,
    • Gregory A. Roth,
    • Nilay S. Shah,
    • Mellanie V. Springer,
    • Marie-Pierre St-Onge,
    • Evan L. Thacker,
    • Sarah M. Urbut,
    • Harriette G.C. Van Spall,
    • Jenifer H. Voeks,
    • Seamus P. Whelton,
    • Nathan D. Wong,
    • Sally S. Wong,
    • Kristine Yaffe,
    • Latha P. Palaniappan,
    2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association, Circulation, 151, 8, (e41-e660), (2025)./doi/10.1161/CIR.0000000000001303
    Abstract
    • Li Chen,
    • Yi Jiang,
    Association Study of MTHFR C677T Polymorphism With Homocysteine Level and Coronary Heart Disease in Elderly Patients , Cardiology Research and Practice, 2025, 1, (2025).https://doi.org/10.1155/crp/6246458
    Crossref
    • Yasir Hassan Elhassan,
    • Fahad Alahmadi,
    • Emad Ali Albadawi,
    • Abdullah Albarakati,
    • Azizah Hendi Aljohany,
    • Naweed SyedKhaleel Alzaman,
    • Muayad Albadrani,
    The Relationship Between Maternal Exposure to Endocrine-Disrupting Chemicals and the Incidence of Congenital Heart Diseases: A Systematic Review and Meta-Analysis, Metabolites, 14, 12, (709), (2024).https://doi.org/10.3390/metabo14120709
    Crossref
    • Benjamin M. Helm,
    • Stephanie M. Ware,
    Clinical Decision Analysis of Genetic Evaluation and Testing in 1013 Intensive Care Unit Infants with Congenital Heart Defects Supports Universal Genetic Testing, Genes, 15, 4, (505), (2024).https://doi.org/10.3390/genes15040505
    Crossref
    • Jorge L. Cervantes-Salazar,
    • Nonanzit Pérez-Hernández,
    • Juan Calderón-Colmenero,
    • José Manuel Rodríguez-Pérez,
    • María G. González-Pacheco,
    • Clara Villamil-Castañeda,
    • Angel A. Rosas-Tlaque,
    • Diego B. Ortega-Zhindón,
    Genetic Insights into Congenital Cardiac Septal Defects—A Narrative Review, Biology, 13, 11, (911), (2024).https://doi.org/10.3390/biology13110911
    Crossref
    • Mingsheng Liu,
    • Yan Xing,
    • Jiufeng Tan,
    • Xiaoliang Chen,
    • Yaming Xue,
    • Licheng Qu,
    • Jianchao Ma,
    • Xuefei Jin,
    Comprehensive summary: the role of PBX1 in development and cancers, Frontiers in Cell and Developmental Biology, 12, (2024).https://doi.org/10.3389/fcell.2024.1442052
    Crossref
    • Seth S. Martin,
    • Aaron W. Aday,
    • Zaid I. Almarzooq,
    • Cheryl A.M. Anderson,
    • Pankaj Arora,
    • Christy L. Avery,
    • Carissa M. Baker-Smith,
    • Bethany Barone Gibbs,
    • Andrea Z. Beaton,
    • Amelia K. Boehme,
    • Yvonne Commodore-Mensah,
    • Maria E. Currie,
    • Mitchell S.V. Elkind,
    • Kelly R. Evenson,
    • Giuliano Generoso,
    • Debra G. Heard,
    • Swapnil Hiremath,
    • Michelle C. Johansen,
    • Rizwan Kalani,
    • Dhruv S. Kazi,
    • Darae Ko,
    • Junxiu Liu,
    • Jared W. Magnani,
    • Erin D. Michos,
    • Michael E. Mussolino,
    • Sankar D. Navaneethan,
    • Nisha I. Parikh,
    • Sarah M. Perman,
    • Remy Poudel,
    • Mary Rezk-Hanna,
    • Gregory A. Roth,
    • Nilay S. Shah,
    • Marie-Pierre St-Onge,
    • Evan L. Thacker,
    • Connie W. Tsao,
    • Sarah M. Urbut,
    • Harriette G.C. Van Spall,
    • Jenifer H. Voeks,
    • Nae-Yuh Wang,
    • Nathan D. Wong,
    • Sally S. Wong,
    • Kristine Yaffe,
    • Latha P. Palaniappan,
    2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association, Circulation, 149, 8, (e347-e913), (2024)./doi/10.1161/CIR.0000000000001209
    Abstract
    • Samantha K. Teixeira,
    • Roberto Pontes,
    • Luiz Fernando G. Zuleta,
    • Jianhui Wang,
    • Darui Xu,
    • Sara Hildebrand,
    • Jamie Russell,
    • Xiaoming Zhan,
    • Mihwa Choi,
    • Miao Tang,
    • Xiaohong Li,
    • Sara Ludwig,
    • Bruce Beutler,
    • Jose E. Krieger,
    Genetic determinants of blood pressure and heart rate identified through ENU-induced mutagenesis with automated meiotic mapping, Science Advances, 10, 9, (2024).https://doi.org/10.1126/sciadv.adj9797
    Crossref
    • Richard M Monaghan,
    • Richard W Naylor,
    • Daisy Flatman,
    • Paul R Kasher,
    • Simon G Williams,
    • Bernard D Keavney,
    FLT4 causes developmental disorders of the cardiovascular and lymphovascular systems via pleiotropic molecular mechanisms, Cardiovascular Research, 120, 10, (1164-1176), (2024).https://doi.org/10.1093/cvr/cvae104
    Crossref
    • Yanting Wu,
    • Kaizhen Su,
    • Ying Zhang,
    • Langchao Liang,
    • Fei Wang,
    • Siyue Chen,
    • Ling Gao,
    • Qiutong Zheng,
    • Cheng Li,
    • Yunfei Su,
    • Yiting Mao,
    • Simeng Zhu,
    • Chaochao Chai,
    • Qing Lan,
    • Man Zhai,
    • Xin Jin,
    • Jinglan Zhang,
    • Xun Xu,
    • Yu Zhang,
    • Ya Gao,
    • Hefeng Huang,
    A spatiotemporal transcriptomic atlas of mouse placentation, Cell Discovery, 10, 1, (2024).https://doi.org/10.1038/s41421-024-00740-6
    Crossref
  11. See more

View Options

View options

PDF and All Supplements

Download PDF and All Supplements

PDF/EPUB

View PDF/EPUB
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Save for later Item saved, go to cart
Purchase Options

Purchase this article to access the full text.

Purchase access to this article for 24 hours

A Screening Approach to Identify Clinically Actionable Variants Causing Congenital Heart Disease in Exome Data
Circulation: Genomic and Precision Medicine
  • Vol. 11
  • No. 3

Purchase access to this journal for 24 hours

Circulation: Genomic and Precision Medicine
  • Vol. 11
  • No. 3
Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Figures

Tables

Media

Share

Share

Share article link

Share

View full text|Download PDF

Comment Response